Skye Bioscience Inc. (SKYE)
| Bid | 4.07 |
| Market Cap | 127.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.12B |
| EPS (ttm) | -0.83 |
| PE Ratio (ttm) | -4.95 |
| Forward PE | -2.57 |
| Analyst | Buy |
| Ask | 5.28 |
| Volume | 4,657,058 |
| Avg. Volume (20D) | 1,100,212 |
| Open | 4.75 |
| Previous Close | 4.25 |
| Day's Range | 4.10 - 5.75 |
| 52-Week Range | 1.14 - 8.36 |
| Beta | 1.67 |
About SKYE
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for SKYE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 weeks ago · https://www.defenseworld.net
Squarepoint Ops LLC Buys Shares of 13,546 Skye Bioscience, Inc. (NASDAQ:SKYE)Squarepoint Ops LLC bought a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exc...
2 weeks ago · https://www.defenseworld.net
Squarepoint Ops LLC Takes Position in Skye Bioscience, Inc. (NASDAQ:SKYE)Squarepoint Ops LLC acquired a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SE...
1 month ago · proactiveinvestors.co.uk
Arecor shares jump 10% on obesity drug partnership with Skye BioscienceShares in Arecor Therapeutics PLC (AIM:AREC) rose 10% in morning trading after the company announced a new development deal with US biotech group Skye Bioscience to improve the formulation of a mid-st...
1 month ago · proactiveinvestors.co.uk
Arecor partners with Skye Bioscience to improve formulation of obesity drugArecor Therapeutics PLC (AIM:AREC) has entered a development partnership with Skye Bioscience Inc (NASDAQ:SKYE), a US-based biotechnology group, to create a more concentrated formulation of an experim...
